Stock Comparison

BEAT vs PFE

Heartbeam Inc vs Pfizer Inc

The Verdict

PFE takes this one.

BEAT

Heartbeam Inc

3.9

out of 10

Risk Trap

Winner

PFE

Pfizer Inc

4.0

out of 10

Proceed with Caution

Head-to-Head

$50M

Market Cap

$146.4B

-1.6

P/E Ratio

19.5

N/A

Profit Margin

11.8%

-571.1%

Return on Equity

8.4%

N/A

Debt-to-Equity

0.7

Aggressive

Overall Risk

Moderate

3.9

DVR Score

4.0

The Deep Dive

BEAT3.9/10

Heartbeam continues to possess intriguing long-term potential anchored by its innovative 3D VECG technology and FDA-cleared AIMIGo, targeting a critical and expanding cardiovascular monitoring market. The leadership has demonstrated relevant expertise and achieved regulatory milestones. However, the company's financial state remains extremely precarious with $0 revenue in Q1 2026, a substantial ne...

Full BEAT Analysis

PFE4.0/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Full PFE Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.